ReviewJournal of pharmacopuncture2019
Rheumatiod Arthritis: An Updated Overview of Latest Therapy and Drug Delivery.
Review in Journal of pharmacopuncture, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDs.Rheumatology and therapy · 2026Article
- Preclinical investigation of hydroxychloroquine loaded ethosomal gel for topical treatment of rheumatoid arthritis.Inflammopharmacology · 2026Article
- Overview of Silk Fibroin Injectable Hydrogels: Advances and Applications in Regenerative Medicine.Advanced healthcare materials · 2026Review
- Brucine-loaded hydrogel microneedles for sustained anti-inflammatory therapy in rheumatoid arthritis: programmable drug release and detachable design.Drug delivery and translational research · 2026Article
- Targeted Delivery of Nucleic Acid Therapeutics: Emerging Carriers and Applications in Common Metabolic and Inflammatory Diseases.International journal of nanomedicine · 2026Review
- A Comprehensive Review on Plant Bioactive Compounds-based Novel Drug Delivery System for the Treatment of Rheumatoid Arthritis.Pharmaceutical nanotechnology · 2026Review
- Emerging Phytochemical Formulations for Management of Rheumatoid Arthritis: A Review.Current drug delivery · 2025Review
- TP-P1-Loaded Thermosensitive Hydrogel Attenuates Rheumatoid Arthritis in a Mouse Model via TLR4/NF-κB Pathway.Journal of inflammation research · 2025Article
- Integrating 3D-printed hydrogels and polymeric nanofibers in a double-layered transdermal patch for the treatment of rheumatoid arthritis.RSC advances · 2024Article
- Engineered self-regulating macrophages for targeted anti-inflammatory drug delivery.Arthritis research & therapy · 2024Article
- JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy.International journal of molecular sciences · 2024Review
- Recent advancements in cartilage tissue engineering innovation and translation.Nature reviews. Rheumatology · 2024Review
- Engineered Self-Regulating Macrophages for Targeted Anti-inflammatory Drug Delivery.Research square · 2024Article
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Nano - Based Therapeutic Strategies in Management of Rheumatoid Arthritis.Recent patents on nanotechnology · 2024Review
- Genetically engineered macrophages derived from iPSCs for self-regulating delivery of anti-inflammatory biologic drugs.Journal of tissue engineering and regenerative medicine · 2024Article
- Research Advances in Nucleic Acid Delivery System for Rheumatoid Arthritis Therapy.Pharmaceutics · 2023Review
- Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments.Journal of nanobiotechnology · 2023Review
- Polymeric Hydrogels for Controlled Drug Delivery to Treat Arthritis.Pharmaceutics · 2022Review
- Yunnan Baiyao Ameliorates Rheumatoid Arthritis in Rats by Shifting the Th17/Treg Cell Balance and Preventing Osteoclast Differentiation.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis is a severe autoimmune disorder, related to joints. It is associated with serious cartilage destruction. This causes disability and reduces the excellence of life. Numerous treatments are existed to combat this disease, however, they are not very efficient and possess severe side effects, higher doses, and frequent administration. Therefore, newer therapies are developed to overcome all these limitations. These include different monoclonal antibodies, immunoglobulins, small molecules used for immunotherapy and transgenes for gene therapy. One of the main goals of these new generation therapeutics is to address the underlying distressing biological processes by specifically targeting the causative agents with fewer systemic side effects and greater patient console. It is very fortuitous that loads of progressive investigations are going on in this field and many of them have entered into the successful clinical trial. But till date, a limited molecule has got FDA clearance and entered the market for treating this devastating disease. This review highlights the overview of conventional therapy and advancements in newer therapeutics including immunotherapy and gene therapy for rheumatoid arthritis. Further, different novel techniques for the delivery of these therapeutics of active and passive targeting are also described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.